9LB.F LEGEND BIOTECH SP.ADS/2

Healthcare Biotechnology Frankfurt Exchange
17.40 EUR
Close of Nov 11, 2026
13.80 31.20
Market cap
EUR 3.38B
P/E
-
P/B
3.16x
ROE
3.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 9LB.F undervalued?

Graham number

The Graham number of LEGEND BIOTECH SP.ADS/2 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LEGEND BIOTECH SP.ADS/2 fundamental analysis

No fundamental analysis for LEGEND BIOTECH SP.ADS/2 yet.

LEGEND BIOTECH SP.ADS/2 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LEGEND BIOTECH SP.ADS/2

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous …

Full company profile